Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00942149 · ClinicalTrials.gov registry record · Phase 1

An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants

A Phase 1 study, sponsored by Duke University.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target

NCT00942149 is a Phase 1 study that has completed, run by Duke University. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00942149, a Phase 1 study, has completed, sponsored by Duke University.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target

Study Summary

This is a safety and pharmacokinetic study of single-dose daptomycin in infants \> 48 hours and \< 120 days of age with suspected systemic infections. The investigators will enroll a total of 24 infants in 4 gestational age/postnatal age cohorts. Interim analyses will be performed after 3 infants are enrolled in each cohort. The investigators anticipate that 6 mg/kg of daptomycin will yield an AUC \<740 mch\*hr/mL.

Interventions

  • DRUG Daptomycin

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2010-01
Est. Completion 2011-12
Phase Phase 1

Sponsor

Duke University

1,725 total trials

What the Registry Record Tells You About NCT00942149

The ClinicalTrials.gov registry entry for NCT00942149 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Daptomycin is the first listed.

NCT00942149 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00942149 about?

NCT00942149 is a clinical study titled "An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants". This is a safety and pharmacokinetic study of single-dose daptomycin in infants \> 48 hours and \< 120 days of age with suspected systemic infections. The investigators will enroll a total of 24 infants in 4 gestational age/postnatal age cohorts. Interim analyses will be performed after 3 infants ar...

What is the current status of trial NCT00942149?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2010-01. Estimated completion is 2011-12.

What interventions are being tested in trial NCT00942149?

The interventions under investigation include: Daptomycin (DRUG).

Who is sponsoring clinical trial NCT00942149?

This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.